Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS228 in Complicated Intra-abdominal Infection
NCT03354754Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2018
- Primary completion
- Sep 2018
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of ancremonam in Intra-abdominal infection (IAI), sponsored by Novartis. Started May 2018; status: terminated.
02
Drugs
ancremonam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT03354754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354754.